---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024277"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:25:57.144674+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma secures $65K convertible note and AU$230K loan; issues warrant for 15M shares

## Summary
- Entered securities purchase agreement with 1800 Diagonal Lending LLC for $65,000 convertible note at 8% interest, convertible at 65% of market price.
- Loan agreement with institutional investor for AU$230,000 at 10% interest, 3-year term; issued warrant for 15M shares at $0.01.
- Proceeds used to repay ~$143,000 convertible note in default; remaining for working capital.
- Convertible note maturity June 29, 2024; prepayment premiums range from 110% to 129%.

## SEC filing metadata
- accession: 0001493152-23-024277
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024277
- JSON: https://secwatch.observer/filing/0001493152-23-024277.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024277.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $65,000 with June Investor at 8% per annum maturing June 29, 2024.
  - Instrument: convertible notes
  - Principal: $65,000
  - Counterparty: June Investor
  - Rate: 8% per annum
  - Maturity: June 29, 2024
  - Event: incurrence
  source text: On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm
- Debt Financings
  Propanc Biopharma, Inc. incurred loan of AU$230,000 with July Investor at 10% maturing July 5, 2026.
  - Instrument: loan
  - Principal: AU$230,000
  - Counterparty: July Investor
  - Rate: 10%
  - Maturity: July 5, 2026
  - Event: incurrence
  source text: On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with June Investor valued at $65,000 (effective 2023-06-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: June Investor
  - Value: $65,000
  - Effective: 2023-06-29
  source text: On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Loan Agreement with July Investor valued at AU$230,000 (effective 2023-07-05).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: July Investor
  - Value: AU$230,000
  - Effective: 2023-07-05
  source text: On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223024277/0001493152-23-024277-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.